Merck and Kelun Biotech Secure Second Phase 3 Victory for Lung Cancer Drug

By Elaine Chen · STAT News · 2026-07-15

STAT News reports that Merck and its Chinese partner Kelun Biotech achieved significant results in a Phase 3 study for their targeted chemotherapy, sac-TMT. When paired with Keytruda, the treatment successfully slowed tumor growth in patients with a specific form of non-squamous

STAT News reports that Merck and its Chinese partner Kelun Biotech achieved significant results in a Phase 3 study for their targeted chemotherapy, sac-TMT. When paired with Keytruda, the treatment successfully slowed tumor growth in patients with a specific form of non-squamous